Browse News
Filter News
Found 41,829 articles
-
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Thermedical Successfully Completes Feasibility Study for Treating Cardiac Arrhythmias Using Pulsed Field Ablation in Combination with SERF Ablation
4/23/2024
Thermedical®, a developer of advanced thermal-ablation systems to treat ventricular arrhythmias, announced today that it has completed a feasibility study utilizing Pulsed Field Ablation (PFA) therapy in combination with its SERF Ablation System and Durablate® Catheter for treating ventricular tachycardia (VT).
-
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
4/23/2024
Response Pharmaceuticals, Inc today announced positive topline results from its Phase 1b clinical trial evaluating the safety and efficacy of RDX-002.
-
Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing
4/23/2024
Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million.
-
Hera Biotech Announces Positive Interim Results From Endometriosis Diagnostic Study
4/23/2024
Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test.
-
CN Bio Raises $21 Million USD in First Close of Series B Investment Round
4/23/2024
CN Bio, a leading provider of single- and multi-organ microphysiological systems, announced it has raised a $21 million investment in the first close of its Series B fundraising round.
-
HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
4/23/2024
HanxBio announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature Portfolio online journal Scientific Reports.
-
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
4/23/2024
PROCEPT BioRobotics today announced that 12 abstracts highlighting its Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas, from May 3 - 6, 2024.
-
Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.
-
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
4/22/2024
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, announced the closing of a $40M Series A financing round.
-
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
4/22/2024
Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.
-
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
4/22/2024
Kraig Biocraft Laboratories, Inc., announces what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial.
-
BoomRay's Radioactive Diagnostic New Drug [18F]BF3-BPA Injection Completes First Subject Enrollment in Phase I Clinical Trial
4/22/2024
BoomRay Pharmaceutical Co., Ltd. (“BoomRay”) announced that the phase I clinical trial of its positron emission tomography (PET) tracer [18F]BF3-BPA injection for the diagnosis of primary and metastatic brain tumors has completed the enrollment of the first subject.
-
Cell Therapy Market Size to Grow At 22.67% CAGR Till 2033
4/22/2024
The global cell therapy market size was valued at USD 4.85 billion in 2023 and is projected to surpass around USD 37.42 billion by 2033, registering a CAGR of 22.67% over the forecast period of 2024 to 2033 according to Nova One Advisor.
-
Synthetic Biology Industry is Rising Rapidly Up to USD 80.17 Bn by 2033
4/22/2024
The global synthetic biology market size was worth around USD 14.09 billion in 2024 and is predicted to grow around USD 80.17 billion by 2033 with a compound annual growth rate (CAGR) of roughly 18.99% between 2024 and 2033 According to a new report by Nova One Advisor.
-
Molecular You Announces Breakthrough in Early Detection of Pancreatic Cancer
4/22/2024
Molecular You has achieved a significant milestone in the early detection of pancreatic cancer.
-
Enrollment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
4/22/2024
Actinogen Medical Limited (ASX: ACW) announces the full enrollment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD).